证券代码：002901 证券简称：大博医疗 公告编号：2025-042 大博医疗科技股份有限公司 关于注销 2024 年股票期权激励计划 部分股票期权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召 开第三届董事会第二十次会议和第三届监事会第十九次会议，审议通过了《关于 注销 2024 年股票期权激励计划部分股票期权的议案》。现将有关情况公告如下： 一、本次激励计划已履行的审批程序 （一）2024 年 9 月 10 日，公司召开第三届董事会第十三次会议，会议审议 通过《关于公司〈2024 年股票期权激励计划（草案）〉及其摘要的议案》《关 于公司〈2024 年股票期权激励计划实施考核管理办法〉的议案》以及《关于提 请股东大会授权董事会办理股权激励相关事宜的议案》。 同日，公司召开第三届监事会第十二次会议，会议审议通过了《关于公司 〈2024 年股票期权激励计划（草案）〉及其摘要的议案》《关于公司〈2024 年 股票期权激励计划实施考核管理办法〉的议案》以及《关于核查公司〈2 ...

中国﹒厦门厦禾路 666 号海翼大厦 A 幢 16-18 楼 电话：86·592·5883666 传真：86·592·5881668 厦门·上海·福州·泉州·龙岩 http://www.tenetlaw.com 中国﹒厦门厦禾路 666 号海翼大厦 A 幢 16-18 楼 厦门·上海·福州·泉州·龙岩 http://www.tenetlaw.com 福建天衡联合律师事务所 关于大博医疗科技股份有限公司 2024 年股票期权激励计划 首次授予股票期权第一个行权期行权条件成就 及注销部分股票期权事项的 法律意见书 福建天衡联合律师事务所 法律意见书 关于大博医疗科技股份有限公司 2024 年股票期权激励计划 首次授予股票期权第一个行权期行权条件成就 及注销部分股票期权事项的法律意见书 致：大博医疗科技股份有限公司 福建天衡联合律师事务所（以下简称"本所"）接受大博医疗科技股份有限 公司（以下简称"大博医疗"、"公司"）的委托，就公司 2024 年股票期权激 励计划（以下简称"激励计划"或"本次激励计划"）相关事宜担任专项法律顾 问，并就本次激励计划首次授予股票期权第一个行权期行权条件成就（以下简称 "本次行权"） ...

（记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，大博医疗（SZ 002901，收盘价：55.85元）10月28日晚间发布三季度业绩公告称，2025年 前三季度营收约18.76亿元，同比增加22.69%；归属于上市公司股东的净利润约4.25亿元，同比增加 77.03%；基本每股收益1.0444元，同比增加80.26%。 截至发稿，大博医疗市值为231亿元。 每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ ...

Group 1 - The core point of the article is that Dabo Medical has approved a plan to use up to 250 million RMB of idle funds to invest in financial products, ensuring that normal operations and fund safety are not affected [1] - The board of directors has authorized the chairman or authorized personnel to make investment decisions within the approved limit and timeframe [1] - Dabo Medical's revenue composition for the first half of 2025 is entirely from the medical device manufacturing industry, accounting for 100% [1] Group 2 - As of the report, Dabo Medical has a market capitalization of 23.1 billion RMB [2]

Group 1 - The core point of the article is that Dabo Medical (SZ 002901) held its 20th meeting of the third board of directors on October 28, 2025, to review proposals related to the revision and establishment of certain governance systems [1] - For the first half of 2025, Dabo Medical's revenue composition is entirely from the medical device manufacturing industry, accounting for 100.0% [1] - As of the time of reporting, Dabo Medical has a market capitalization of 23.1 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a "slow bull" new pattern [1]

Core Viewpoint - The company reported significant revenue and profit growth in the third quarter of 2025, indicating strong operational performance and improved financial conditions [1] Financial Performance - The company's revenue for the third quarter reached 666 million yuan, representing a year-on-year increase of 17.82% [1] - The net profit attributable to shareholders for the third quarter was 180 million yuan, showing a substantial year-on-year growth of 77.49% [1] - For the first three quarters, the total revenue amounted to 1.876 billion yuan, reflecting a year-on-year growth of 22.69% [1] - The net profit attributable to shareholders for the first three quarters was 425 million yuan, with a year-on-year increase of 77.03% [1] Growth Drivers - The growth in performance is primarily attributed to an increase in operating income and a decrease in financial expenses due to rising exchange gains [1]

人民财讯10月28日电，大博医疗（002901）10月28日发布2025年三季报，公司第三季度营业收入6.66亿 元，同比增长17.82%；净利润1.8亿元，同比增长77.49%。2025年前三季度营业收入18.76亿元，同比增 长22.69%；净利润4.25亿元，同比增长77.03%；基本每股收益1.0444元。 ...

【大博医疗：前三季度净利润同比增长77.03%】智通财经10月28日电，大博医疗(002901.SZ)公告称， 公司发布2025年第三季度报告，第三季度营收为6.66亿元，同比增长17.82%；归属于上市公司股东的净 利润为1.80亿元，同比增长77.49%。前三季度营收为18.76亿元，同比增长22.69%；归属于上市公司股 东的净利润为4.25亿元，同比增长77.03%。业绩增长主要系营业收入增加及财务费用因汇兑收益上升而 下降所致。 转自：智通财经 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥665,815,103.16, representing a year-on-year increase of 17.82%[5] - Net profit attributable to shareholders was ¥180,387,474.59, up 77.49% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥123,275,408.71, an increase of 38.44% year-on-year[5] - Total operating revenue for Q3 2025 reached ¥1,876,254,824.66, an increase of 22.7% compared to ¥1,529,257,676.10 in Q3 2024[19] - Net profit for Q3 2025 was ¥448,823,669.30, up 70.5% from ¥263,149,336.98 in Q3 2024[20] - Basic earnings per share for Q3 2025 were ¥1.0444, compared to ¥0.5794 in Q3 2024, reflecting a significant increase[21] - Operating profit for Q3 2025 was ¥514,358,734.98, a rise of 78.2% from ¥288,603,968.09 in Q3 2024, indicating improved operational efficiency[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,554,839,533.75, reflecting a growth of 3.08% from the end of the previous year[5] - Total assets as of Q3 2025 amounted to ¥4,554,839,533.75, up from ¥4,418,929,603.41 in the previous year[18] - Total liabilities decreased to ¥1,117,390,868.79 from ¥1,237,317,657.89 year-over-year, indicating improved financial stability[18] - Total current assets increased to ¥2,986,575,438.17 from ¥2,811,610,722.46[16] - Trade receivables rose to ¥303,506,186.43 from ¥235,579,112.44, indicating a growth of approximately 28.8%[16] - Inventory remains stable at ¥1,271,571,730.77, slightly down from ¥1,272,779,370.13[16] - Fixed assets decreased to ¥1,065,320,071.43 from ¥1,101,179,566.26[16] Equity and Shareholder Information - The total equity attributable to shareholders rose to ¥3,336,569,852.45, marking an increase of 8.37% from the previous year[5] - The company's total equity increased to ¥3,437,448,664.96 in Q3 2025, compared to ¥3,181,611,945.52 in Q3 2024, showing strong growth in shareholder value[18] - Total number of common shareholders at the end of the reporting period is 22,765[12] - The largest shareholder, Guangxi Dabo Business Communication Venture Capital Co., Ltd., holds 23.46% of shares, totaling 97,124,098 shares[12] - The top ten shareholders account for a significant portion of the company's equity, with the top three holding over 63% combined[12] - The company has a total of 7,409,900 shares held in the repurchase special securities account, representing 1.79% of total shares[13] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[13] Cash Flow and Investments - The company reported a significant increase in cash flow from operating activities, with a net amount of ¥468,292,048.05, up 124.26% year-to-date[5] - Operating cash inflow for the current period was $2,125,257,418.09, an increase of 22.3% from $1,737,849,496.04 in the previous period[23] - Net cash flow from operating activities was $468,292,048.05, up 124.5% from $208,812,403.51 year-over-year[23] - Cash outflow from investing activities totaled $1,605,258,126.37, an increase of 31.3% compared to $1,222,498,801.80 in the previous period[24] - Net cash flow from investing activities was -$319,058,783.65, a decline from a positive $94,896,830.93 in the previous period[24] - Cash inflow from financing activities was $77,570,176.00, up from $67,861,081.00 in the previous period[24] - Net cash flow from financing activities was -$338,987,025.69, an improvement from -$418,803,870.64 year-over-year[24] - The ending cash and cash equivalents balance was $60,131,962.39, down from $159,891,883.23 in the previous period[24] - Cash received from sales of goods and services was $2,046,889,518.51, compared to $1,646,466,291.02 in the previous period[23] - Total cash outflow for employee payments was $620,292,294.94, an increase from $543,317,049.92 in the previous period[23] - Cash received from other operating activities was $75,800,724.44, slightly down from $80,759,720.17 in the previous period[23] Research and Development - Research and development expenses for Q3 2025 were ¥250,245,754.07, an increase of 16.6% from ¥214,640,411.75 in Q3 2024, highlighting ongoing investment in innovation[19] Fair Value and Government Subsidies - The fair value changes of financial assets resulted in a profit of ¥37,714,385.71, a substantial increase of 3523.41% compared to the previous year[9] - The company received government subsidies totaling ¥30,763,148.25 during the reporting period, contributing to its financial performance[6]

Core Points - The Bioeconomy Index (970038) closed at 2277.51 points, down 0.16%, with a trading volume of 18.883 billion yuan and a turnover rate of 1.2% [1] - Among the index constituents, 23 stocks rose while 27 fell, with Iwubio leading the gainers at 6.71% and Meiya Optoelectronics leading the decliners at 3.02% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 225.09 yuan, and a market cap of 272.908 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 116.50 yuan, and a market cap of 47.525 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.97 yuan, and a market cap of 56.849 billion yuan [1] - Other notable constituents include Shishihistory (sz002252), Table Pharmaceutical (sz300347), and Muyuan Foods (sz002714) [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 871 million yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [3] - Key capital flows include: - Iwubio (300357) with a net inflow of 52.9277 million yuan from institutional investors [3] - Dabo Medical (002901) with a net inflow of 31.8434 million yuan from institutional investors [3] - Changchun High-tech (000661) with a net inflow of 27.6452 million yuan from institutional investors [3]